Compare GE Aerospace (GE) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE Aerospace vs Mesoblast Limited — how do they compare? GE Aerospace trades at $306.49 (market cap $315.02B), while Mesoblast Limited trades at $13.8 (market cap $1.81B). The key difference: GE Aerospace is far larger — about 174× Mesoblast Limited's market cap, and GE Aerospace pays a 0.62% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold GE Aerospace for 111 Days and Mesoblast Limited for 14 Days on average.
| GE | MESO | |
|---|---|---|
Market Cap | $315.02B | $1.81B |
Volume | 3,800,907 | 240,620 |
Sector | Industrials | Health |
52-Week High | $381.22 | $20.96 |
52-Week Low | $273.25 | $13.19 |
Typical Hold Time | 111 Days | 14 Days |
Enterprise Value | $324.84B | $1.89B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE Aerospace trades at $305.62, down 1.22% amid broader market weakness, with technical indicators showing bearish momentum below key moving averages. Fundamentally, the company demonstrates strong profitability with 17.72% net margins and consistent earnings beats, though valuation multiples appear elevated. Recent news highlights the strategic $12 billion CPP acquisition to address supply chain constraints while maintaining robust shareholder returns through dividends and buybacks.
The outlook remains constructive given strong defense demand and operational execution, but high valuation and acquisition integration risks warrant caution. Analyst consensus is strongly bullish with a $409.60 price target representing 34% upside, though near-term technical pressure may persist until the Q3 earnings report provides clearer direction.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
